<![CDATA[Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer]]>

Study HighlightsTreatment with daraxonrasib at the 300-mg dose level in patients with second-line RAS G12-mutated PDAC, any RAS mutation in the second line, and any RAS mutation in the third-line setting or later produced ORRs of 35%, 29%, and 20%, respectively.Safety data revealed that 96% of patients experienced TRAEs with the agent; however, the majority were low-grade gastrointestinal or cutaneous issues, and no treatment-related deaths were reported.Daraxonrasib is currently being evaluated in 3 phase 3 studies, including the global phase 3 RASolute 303 trial, where its efficacy will be compared with standard-of-care chemotherapy in the second-line setting.